Target intelligence / Profile preview

ATP synthase mitochondrial F1 complex beta subunit (ATP5B)

Target
ATP5B
Molecular classification
Enzyme, Mitochondrial enzyme subunit, Rotary ATPase, Energy metabolism protein
01

Overview

The **ATP synthase mitochondrial F1 complex beta subunit** (*ATP5B*) is a core component of the mitochondrial ATP synthase (Complex V), responsible for the enzyme’s catalytic activity in synthesizing ATP from ADP and inorganic phosphate, utilizing the proton gradient across the inner mitochondrial membrane. The F1 complex, protruding into the mitochondrial matrix, is composed of three alpha and three beta subunits arranged alternately. The beta subunit specifically contains the primary catalytic sites for nucleotide binding and ATP synthesis, undergoing conformational changes in response to the rotational mechanism driven by proton flow through the FO complex. Mutations or defects in ATP5B can result in severe mitochondrial diseases, and the protein is essential for all cellular energy-dependent processes[1][2][3][5][6]. ATP synthase inhibitors (such as oligomycin) effectively shut down mitochondrial ATP production, illustrating its importance and the toxicity of its inhibition in humans.

Other names
ATP synthase beta subunitF1-ATPase beta subunitATP5BComplex V beta subunit
02

Mechanism of action

Direct enzyme inhibition (e.g., oligomycin binds to ATP synthase and blocks proton channel, halting ATP synthesis) Rotational catalysis interference (experimental compounds may target the enzyme’s rotation or conformational states)

03

Biological functions

ATP synthesis (catalyzes ATP formation from ADP and phosphate)Cellular energy productionOxidative phosphorylationProton-coupled catalysis
04

Disease associations

Mitochondrial disease (defects can cause mitochondrial complex V deficiency)Neurodegenerative diseaseOther metabolic disorders
05

Safety considerations

Inhibition can impair energy metabolism and is toxic for healthy cells (critical for cell viability)Deficiencies or mutations can result in multi-systemic mitochondrial disease
06

Interacting drugs

Oligomycin (inhibitor of mitochondrial ATP synthase)

2 more in the full profile.

07

Biomarkers

ATP5B protein and gene expression as a marker for mitochondrial functionDecreased ATP synthase activity as indicator of mitochondrial disorders

Beyond the preview

Go deeper on ATP synthase mitochondrial F1 complex beta subunit (ATP5B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP synthase mitochondrial F1 complex beta subunit (ATP5B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call